Michael Zhong

99 Commercial Rd
Melbourne, VIC 3004, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Lymphocyte count polygenicity underlies dimethyl fumarate-associated lymphopenia in multiple sclerosis.

Lymphocyte count polygenicity underlies dimethyl fumarate-associated lymphopenia in multiple sclerosis.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: August 18, 2026

Modern diagnosis and treatment of multiple sclerosis: advances, challenges, and future directions.

Modern diagnosis and treatment of multiple sclerosis: advances, challenges, and future directions.

Journal: Autoimmunity reviews

Published: May 11, 2026

Circulatory immune cell counts and clinical outcomes in multiple sclerosis relapse versus remission.

Circulatory immune cell counts and clinical outcomes in multiple sclerosis relapse versus remission.

Journal: Journal of the neurological sciences

Published: February 05, 2026

Mural gallbladder haematoma in a Parson Russell Terrier.

Mural gallbladder haematoma in a Parson Russell Terrier.

Journal: Australian veterinary journal

Published: July 29, 2025

Consensus recommendations on multiple sclerosis management in Australia and New Zealand: part 2.

Consensus recommendations on multiple sclerosis management in Australia and New Zealand: part 2.

Journal: The Medical journal of Australia

Published: October 09, 2024

Consensus recommendations on multiple sclerosis management in Australia and New Zealand: part 1.

Consensus recommendations on multiple sclerosis management in Australia and New Zealand: part 1.

Journal: The Medical journal of Australia

Published: April 25, 2024

Real-world efficacy, roll-out and uptake of intramuscular tixagevimab/cilgavimab as COVID-19 pre-exposure prophylaxis in people with multiple sclerosis and neuroimmunological conditions during the COVID-19 pandemic.

Real-world efficacy, roll-out and uptake of intramuscular tixagevimab/cilgavimab as COVID-19 pre-exposure prophylaxis in people with multiple sclerosis and neuroimmunological conditions during the COVID-19 pandemic.

Journal: BMJ neurology open

Published: February 11, 2024

Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60.

Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: October 27, 2023

Leukocyte telomere length in multiple sclerosis: relationship between disability severity and pregnancy history.

Leukocyte telomere length in multiple sclerosis: relationship between disability severity and pregnancy history.

Journal: Multiple sclerosis and related disorders

Published: July 20, 2023

Neutropaenia complications from Ocrelizumab and Rituximab treatment.

Neutropaenia complications from Ocrelizumab and Rituximab treatment.

Journal: Multiple sclerosis and related disorders

Published: January 30, 2023

Prediction of relapse activity when switching to cladribine for multiple sclerosis.

Prediction of relapse activity when switching to cladribine for multiple sclerosis.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: July 27, 2022

Prediction of multiple sclerosis outcomes when switching to ocrelizumab.

Prediction of multiple sclerosis outcomes when switching to ocrelizumab.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: October 08, 2021

Showing 1-12 of 20

Last Updated: 09/26/2026